Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
26 sept. 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital...
Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference
05 sept. 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
20 août 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of...
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
06 août 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancerCRB-701 Phase 1 dose...
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
30 juil. 2024 08h50 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
01 juin 2024 10h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and...
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
30 mai 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
23 mai 2024 17h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster...
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
09 mai 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic...